As GH replacement therapy might improve the above symptoms [18] among survivors of childhood acute lymphoblastic leukemia and CNS tumors, provocative endocrine follow-up testing for isolated GH deficiency, e.g. by insulin tolerance test (ITT), is crucial to establish a robust diagnosis for the timely implementation of GH replacement therapy [17]. The gene discussed is GH1; the disease is acute lymphoblastic leukemia.